Abstract
Background
Adult-onset Still disease (AOSD) is a systemic auto-inflammatory disorder that can be divided into monocyclic, polycyclic and chronic arthritis subtypes based on the clinical course. Since the prognoses of the three patterns of AOSD are substantially different, it is important to identify clinical indices that can be used to differentiate them.
Objectives
To investigate the clinical features of the three patterns of AOSD in order to determine possible prognostic factors.
Materials & Methods
Clinical records of inpatients admitted with a probable diagnosis of AOSD to the Second Xiangya Hospital of Central South University between 2009 and 2019 were retrospectively studied. Ninety patients were divided into a monocyclic group, a polycyclic group and a chronic arthritis group.
Results
The average age at onset was 39.01 ± 13.04 years, and female to male ratio was 3.3. Elevated white blood cell (WBC) count, even beyond 15 × 109/L, and increased serum level of interleukin-6 (IL-6) >5.3 pg/mL (upper limit of normal value) were associated with the recurrence of AOSD, while the presence of rash and increased level of alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) were more commonly seen in the monocyclic group.
Conclusion
Our results indicate that gender, presence of rash, WBC count, serum level of IL-6, and ALT and/or AST are promising prognostic factors for AOSD. However, larger cohorts are needed to validate these factors due to the limitations of the retrospective study design and relatively small sample size.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Ruscitti P, Giacomelli R. Pathogenesis of adult onset still’s disease: current understanding and new insights. Expert Rev Clin Immunol 2018; 14: 965–76.
Magadur-Joly G, Billaud E, Barrier JH, et al. Epidemiology of adult Still’s disease: estimate of the incidence by a retrospective study in west France. Ann Rheum Dis 1995; 54: 587–90.
Evensen KJ, Nossent HC. Epidemiology and outcome of adult-onset Still’s disease in Northern Norway. Scand J Rheumatol 2006; 35: 48–51.
Balci MA, Pamuk ON, Pamuk GE, Uzundere FK, Donmez S. Epidemiology and outcome of adult-onset Still’s disease in Northwestern Thrace region in Turkey. Clin Exp Rheumatol 2015; 33: 818–23.
Asanuma YF, Mimura T, Tsuboi H, et al. Nationet al. epidemiological survey of 169 patients with adult Still’s disease in Japan. Mod Rheumatol 2015; 25: 393–400.
Ohta A, Yamaguchi M, Tsunematsu T, et al. Adult Still’s disease: a multicenter survey of Japanese patients. J Rheumatol 1990; 17: 1058–63.
Hu QY, Zeng T, Sun CY, et al. Clinical features and current treatments of adult-onset Still’s disease: a multicentre survey of 517 patients in China. Clin Exp Rheumatol 2019; 37(Suppl 121): 52–7.
Zeng T, Zou YQ, Wu MF, Yang CD. Clinical features and prognosis of adult-onset still’s disease: 61 cases from China. J Rheumatol 2009; 36: 1026–31.
Kong XD, Xu D, Zhang W, Zhao Y, Zeng X, Zhang F. Clinical features and prognosis in adult-onset Still’s disease: a study of 104 cases. Clin Rheumatol 2010; 29: 1015–9.
Wakai K, Ohta A, Tamakoshi A, et al. Estimated prevalence and incidence of adult Still’s disease: findings by a nationet al. epidemiological survey in Japan. J Epidemiol 1997; 7: 221–5.
Govoni M, Bortoluzzi A, Rossi D, Modena V. How I treat patients with adult onset Still’s disease in clinical practice. Autoimmun Rev 2017; 16: 1016–23.
Fautrel B. Adult-onset Still’s disease. Best Pract Res Clin Rheumatol 2008; 22: 773–92.
Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol 1992; 19: 424–30.
Fautrel B, Zing E, Golmard JL, et al. Proposal for a new set of classification criteria for adult-onset still disease. Medicine (Baltimore) 2002; 81: 194–200.
Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets for adult-onset Still’s disease. Nat Rev Rheumatol 2018; 14: 603–18.
Liu Y, Xia C, Chen J, Fan C, He J. Elevated circulating proinflammatory low-density granulocytes in adult-onset Still’s disease. Rheumatology (Oxford) 2021; 60: 297–303.
Maria AT, Quellec AL, Jorgensen C, Touitou I, Rivière S, Guilpain P. Adult onset Still’s disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions. Autoimmun Rev 2014; 13: 1149–59.
Gabay C, Fautrel B, Rech J, et al. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease. Ann Rheum Dis 2018; 77: 840–7.
Cush JJ, Medsger TA Jr., Christy WC, Herbert DC, Cooperstein LA. Adult-onset still’s disease. Arthritis Rheum 1987; 30: 186–94.
Ruscitti P, Cipriani P, Masedu F, et al. Adult-onset Still’s disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers. BMC Med 2016; 14: 194.
Sfriso P, Priori R, Valesini G, et al. Adult-onset Still’s disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients. Clin Rheumatol 2016; 35: 1683–9.
Kim Y, Koo B, Kim Y, Lee C, Yoo B. Clinical features and prognosis in 82 patients with adult-onset Still’s disease. Clin Exp Rheumatol 2014; 32: 28–33.
Kalyoncu U, Solmaz D, Emmungil H, et al. Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still’s disease: Data from a large multicenter cohort. J Autoimmun 2016; 69: 59–63.
Giacomelli R, Ruscitti P, Shoenfeld Y. A comprehensive review on adult onset Still’s disease. J Autoimmun 2018; 93: 24–36.
Efthimiou P, Paik PK, Bielory L. Diagnosis and management of adult onset Still’s disease. Ann Rheum Dis 2006; 65: 564–72.
Pouchot J, Sampalis JS, Beaudet F, et al. Adult Still’s disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore) 1991; 70: 118–36.
Santa E, McFalls J, Sahu J, Lee J. Clinical and histopathological features of cutaneous manifestations of adult-onset Still disease. J Cutan Pathol 2017; 44: 591–5.
Sun N, Brezinski E, Berliner J, et al. Updates in adult-onset Still disease: Atypical cutaneous manifestations and associations with delayed malignancy. J Am Acad Dermatol 2015; 73: 294–303.
Kadavath S, Efthimiou P. Adult-onset Still’s disease-pathogenesis, clinical manifestations, and new treatment options. Ann Med 2015; 47: 6–14.
Cozzi A, Papagrigoraki A, Biasi D, Colato C, Girolomoni G. Cutaneous manifestations of adult-onset Still’s disease: a case report and review of literature. Clin Rheumatol 2016; 35: 1377–82.
Narula N, Narula T, Abril A. Seizing the clinical presentation in adult onset Still’s disease. An extensive literature review. Autoimmun Rev 2015; 14: 472–7.
Mitrovic S, Fautrel B. New markers for adult-onset Still’s disease. Joint Bone Spine 2018; 85: 285–93.
Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Sève P. Adult-onset Still’s disease. Autoimmun Rev 2014; 13: 708–22.
Jia J, Shi H, Liu M, et al. Cytomegalovirus infection may trigger adult-onset Still’s disease onset or relapses. Front Immunol 2019; 10: 898.
Feng M, Gao Y, Yang Y, Li Q. Epidemiological characteristics of herpes simplex virus. Chin J Microbiol Immunol 2019; 12: 937–50.
Qiao J, Zhou S, Li S, et al. Histopathological diagnosis of persistent pruritic eruptions associated with adult-onset Still’s disease. Histopathology 2019; 74: 759–65.
Rao S, Li Q, Wu H, et al. Juxtaposition of IL-1β and IFN-γ expression and apoptosis of keratinocytes in adult-onset Still’s disease. Expert Rev Clin Immunol 2019; 15: 1341–50.
Li S, Zheng S, Tang S, et al. Autoinflammatory pathogenesis and targeted therapy for adult-onset Still’s disease. Clin Rev Allergy Immunol 2020; 58: 71–81.
Han J, Suh C, Jung J, et al. Serum levels of interleukin 33 and soluble ST2 are associated with the extent of disease activity and cutaneous manifestations in patients with active adult-onset Still’s disease. J Rheumatol 2017; 44: 740–7.
Girard C, Rech J, Brown M, et al. Elevated serum levels of free interleukin-18 in adult-onset Still’s disease. Rheumatology (Oxford) 2016; 55: 2237–47.
Néel A, Wahbi A, Tessoulin B, et al. Diagnostic and management of life-threatening adult-onset Still disease: a French nationet al. multicenter study and systematic literature review. Crit Care 2018; 22: 88.
Castañeda S, Blanco R, González-Gay MA. Adult-onset Still’s disease: advances in the treatment. Best Pract Res Clin Rheumatol 2016; 30: 222–38.
Masson C, Loët XL, Lioté F, et al. Adult Still’s disease. Part II. Management, outcome, and prognostic factors. Rev Rhum Engl Ed 1995; 62: 758–65.
Acknowledgements
We acknowledge all the colleagues of the Second Xiangya Hospital of Central South University who have made contributions to diagnosing and treating the patients with adult onset Still’s disease.
Funding
This work was supported by grants from the National Natural Science Foundation of China (No. 81502732) and the Hunan Provincial Natural Science Foundation of China (No. 2021JJ40848) to YL.
Author information
Authors and Affiliations
Corresponding authors
About this article
Cite this article
Tan, S., Chen, Z., Qiu, Y. et al. Prognostic factors for adult-onset Still disease: a retrospective analysis of 90 patients in China. Eur J Dermatol 32, 56–63 (2022). https://doi.org/10.1684/ejd.2022.4192
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1684/ejd.2022.4192